BridgeBio Oncology Therapeutics (BBOT) is a biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.
Investors 2
Mentions in press and media 2
| Date | Title | Description |
| 28.02.2025 | BridgeBio's KRAS-focused cancer spinout backs SPAC as path to Nasdaq | For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. While interest in this path has died down in recent years, BridgeBio’s former cancer unit thinks it could work for them.
BridgeBio Oncology ... |
| - | BridgeBio Oncology Therapeutics | “Leadership Eli Wallace, Ph.D. – CEO Pedro Beltran, Ph.D. – CSO Board of Directors Frank McCormick, Ph.D. (Chair) Neil Kumar, Ph.D. Raymond Kelleher, M.D., Ph.D. Michelle Doig Our Programs bbo-8520, a KRASG12C(ON) inhibitor Phase 1 ONKORAS-... |
Reviews 0
